KEKatya Elgart

Katya Elgart

*This is an algorithmically generated author record based on publicly available information.

Katya Elgart has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A novel multiplexed immunoassay for surface‐exposed proteins in plasma extracellular vesicles

    by Emma Tordoff, Jillian Allen, Katya Elgart, Ahmed Elsherbini, Vrinda Kalia, Haotian Wu, Erden Eren, Dimitrios Kapogiannis, Olesia Gololobova, Kenneth Witwer, et al.

    Small membranous extracellular vesicles (EV) incorporate proteins and nucleic acids from the parent cell. Proteins exposed on EV surface are dictated by cellular origin and biogenesis pathway. To better understand the EV origin and function, it is important to develop methods that reveal surface protein composition of heterogeneous EV populations in culture supernatants and in biofluids. Tetraspanins CD9, CD63, and CD81 are common and abundant EV markers. However, their relative enrichment (profile) on EVs of specific cellular origins is not fully elucidated. We introduce LuminEV, a novel version of the Luminex assay for the multiplexed analysis of EV surface proteins. Optimized LuminEV reagents enable direct, specific, and sensitive measurements of EV markers in biofluids and in culture supernatants, bypassing EV isolation step. LuminEV assay for CD9, CD63, and CD81 was validated by comparing simplex and multiplex measurements, establishing linearity, spike‐in recovery, inter‐ and intra‐assay precision, and reproducibility between operators. LuminEV measurements of CD9, CD63, and CD81 in conditioned media from 15 cell lines revealed strong variations between cell types and showed high sensitivity, which enabled EV detection without prior concentration. Using tetraspanin levels as a readout, we noted suppression and induction of EV release from the cultured cells by GW6869 and monensin. Measurement of EV CD9, CD63, and CD81 in blood plasma from 70 disease‐free donors showed respective abundance of 72, 16, and 12%. CD63 displayed weak, albeit significant, negative correlation with age and was slightly lower in female samples. The assay was then used to detect cell type‐specific EV surface markers, including CD235a (erythrocytes), GAP43 (neurons), and CD68 (macrophages), and to detect differences in tetraspanin profiles between healthy and diseased donors. In summary, LuminEV offers robust and sensitive approach for multiplexed assessment of EV surface proteins, to facilitate the research into EV biology, biomarker, and therapeutic applications.


  • Open Access

    Neuron‐derived extracellular vesicles blood‐based diagnosis of synuclein TDP43 autophagy and synaptic dysfunction pathologies

    by Erez Eitan, Katya E Elgart, Sara Rau, Emma Van Debrake, Olga Volpert

    Background: Stratifying dementia into different subgroups based on specific pathologies can facilitate the development of more effective treatments for subgroups of individuals with dementia. Effective stratification relies on reliable biomarkers. Neuron‐derived extracellular vesicles (NDEs) are lipid structures released by neurons into the extracellular space, and some get into the bloodstream. NDEs carry proteins and RNA that reflect their cell of origin and thus provide a promising biomarker platform.Method: NeuroDex developed two methods. ExoSORT is an optimized NDE isolation platform by immunoaffinity, where NDEs are captured with antibodies against the neuronal‐specific markers GAP43 and NLGN3. LuminEV is an intact extracellular vesicle (EV) immunoassay based on the Luminex platform. Antibodies against a potential biomarker, general EV marker, and IgG (negative control) are multiplexed to generate a robust assay.Result: The vesicular nature and size of NDEs were confirmed by electron microscopy and nanoparticle tracking. EV markers were ascertained by western blot and proteomic analyses, and capture specificity was demonstrated by significantly elevated neuron‐specific proteins and mRNA levels compared to procedural control (IgG). Capture efficiency (∼80%) and precision (CV < 20%) demonstrated recovery of spiked NDEs. Measurements of αSYN following ExoSORT with an MSD assay and on EVs with the LuminEV generated a separation with 83% sensitivity and 86% specificity (45 Parkinson and 30 healthy controls plasma samples). LC3, an autophagy marker, was also measured following ExoSORT and was significantly (P<0.03) elevated in PD and Alzheimer’s disease (AD) (P<0.02, N = 30) plasma samples. TDP43 was also significantly (P<0.004) higher in AD plasma samples following ExoSORT. The synaptic marker GLUR2 was measured by the LuminEV assays and was significantly (P<0.001) reduced in AD and PD plasma samples. Its level was also significantly (P<0.03) correlated with the patient’s cognitive score.Conclusion: Immunoaffinity isolation of EVs from plasma samples according to their cell of origin is a promising biomarker platform. We demonstrate the NDEs isolation selectivity, specificity, and precision. We also show the platform’s potential to identify pathologies like αSYN, TDP43, autophagy, and synaptic dysfunction; this reflects the potential for patient stratification.